2024-03-29 03:23:30 ET
Summary
- Eli Lilly's stock price rise continues unabated in 2023, backed by strong topline growth in 2023 and a sunny outlook for 2024.
- Its diabetes treatments look particularly encouraging, with Mounjaro's 11x revenue increase last year and a great start to Zepbound at the end of 2023.
- While its market multiples look stretched for now, over the medium to long term, they too look better and the stock's exceptional long-term performance is hard to ignore.
...
Read the full article on Seeking Alpha
For further details see:
Eli Lilly: Diabetes And Weight Management Treatments Are The Winning Tickets